Skip to main content
Download PDF

Effect of ABO blood group on postoperative overall survival and recurrence-free survival rate in patients with hepatocellular carcinoma after hepatectomy: a multi-center retrospective cohort study

BMC Surgery volume 23, Article number: 324 (2023) Cite this article

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. The survival rate after hepatectomy as the first line of treatment for HCC depends on various factors. This study evaluated the association of the ABO blood group and Rh with overall survival (OS) and Recurrence-free survival (RFS) rate after hepatectomy.

Methods

This multicenter retrospective cohort study reviewed the medical files of 639 HCC patients who underwent hepatectomy from 2010 to 2022 in three medical centers affiliated with the Iran University of Medical Sciences. Patient data, including demographic, clinical, tumor characteristics, and post-surgery outcomes, were collected by referring to the patient’s medical profiles. The Cox proportional hazard investigated the relationship between ABO blood group type and OS and RFS rate after hepatectomy.

Results

The five-year OS and RFS rates were 25.4% and 18.7%, respectively. The five-year OS (Lok rank:40.89, P:0.001) and RFS rate in patients with blood type A were significantly lower than in non-A patients. (Lok rank:10.8, P:0.001) The multivariate Cox analysis showed that blood type A, age < 45 years, tumor size > 5 cm, Poor tumor differentiation, presence of metastasis, The number of involved lymph nodes ≤ 2, and serum Alpha-Fetoprotein)AFP( level ≥ 400 were significantly related to the decreased survival rate of HCC patients after hepatectomy (P < 0.05) There was no significant association between Rh with OS and RFS (P > 0.05).

Conclusion

Blood group type A, compared to non-A, can be associated with decreased OS and RFS rates in patients with HCC after hepatectomy.

Peer Review reports

Introduction

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. According to the International Agency for Research on Cancer (IARC), it is estimated that the annual number of new cases and deaths from liver cancer by 2040 will be more than 55% increase [1]. The prevalence of HCC is increasing in Asian and African countries and Western countries [2, 3].

HCC is one of the most important and intensifying global health challenges, especially in developing countries [4]. HCC is more common in men than women [5]. Hepatitis B is the most common cause of HCC [5, 6]. HCC, With a 5-year survival rate of 18%, is the third leading cause of cancer death worldwide, indicating the high lethality of this cancer [3, 7]. According to various studies, the 5-year recurrence rate of HCC has been reported between 4.9% and 39.9% [8], indicating that treating this cancer requires a multidisciplinary approach [8].

Hepatectomy, as the first line of treatment for HCC in patients with preserved liver function, is the best treatment method compared to local ablation and chemoembolization [9,10,11,12]. However, the survival rate of these patients is still short and unsatisfactory due to the high recurrence of HCC after hepatectomy [13,14,15]. The survival and recurrence rate of HCC after hepatectomy depends on factors such as tumor stage, maximum tumor diameter, degree of tumor differentiation and, GGT levels [16], histological grade of metastasis, age of patients, body mass index, and alpha-fetoprotein (AFP) levels [17,18,19,20,21,22].

Recent studies have shown the relationship between the ABO blood group type and the survival rate of some cancers [23,24,25]. Many studies reported that the ABO blood group type is associated with HCC survival after hepatectomy [22, 26]. While A. Oral et al., did not report a significant relationship between the type of blood group with the survival rate of HCC after hepatectomy [27]. The distribution of blood groups in different countries is different [28].

Based on our knowledge, limited studies have investigated the association of blood group type with overall survival and recurrence-free survival rate of HCC patients after hepatectomy. Considering the subject’s importance [26, 27], this retrospective cohort study aimed to evaluate the effect of the ABO blood group and RH factor on OS and RFS rates after Hepatectomy.

Methods

Patient characteristics

The Iran University of Medical Sciences ethics committee approved the present study with the code(IR.IUMS.REC.1401.925). In this multicenter retrospective cohort study, the medical profiles of 956 patients with HCC who underwent hepatectomy between 2010 and 2022 in hospitals affiliated with Iran Medical Sciences were reviewed. Six hundred forty-one patients were included. The definitive diagnosis of HCC was made based on pathology and biopsy findings and with an oncologist’s opinion.

Inclusion criteria included patients with a definite diagnosis of HCC and follow-up of at least six months after surgery. Secondary HCC (cases that did not originate from the liver), incomplete patient records, simultaneous suffering from other cancers, and lack of access to the blood bank were defined as the exclusion criterion.

Data collection

Patient data were collected using a three-part checklist, including demographic information, clinical and laboratory findings, tumor characteristics, and post-surgery outcomes by the researcher by referring to the medical profiles. Demographic characteristics included age, sex, education level, Body mass index (BMI), family history of HCC, alcohol consumption, and smoking. The laboratory and clinical information of the patients (hepatitis, hepatitis type, ALP level (ng/ml), Child–Pugh stage, ABO blood group e, and RH factor were. Tumor characteristics included tumor size, number of lymph nodes, cancer stage, tumor differentiation, and metastasis, which were collected by referring to the pathological findings of the patients. The outcomes investigated in this study included the duration of the follow-up, the median survival, the five-year OS, and the RFS rates based on the type of blood group.

Tumor characteristics were classified according to the AJCC 7th Edition Staging System for HCC guidelines [29]. Tumor-node-metastasis index (TNM) classification in this study includes tumor size (< 5 cm/ > 5 cm), number of involved lymph nodes (< 2 and ≥ 2), and presence of metastasis (positive/negative). Survival was defined as the time interval between hepatectomy and death.

Statistical analysis

Stata 17 and SPSS version 22 software were used for data analysis. Mean ± standard deviation was used to report quantitative variables. Qualitative variables were reported with frequency and (%). Kaplan–Meier was used to estimate patients’ OS and RFS rates after hepatectomy based on tumor characteristics and ABO blood group type. The significance of the Kaplan–Meier estimate for patient survival rate was reported using the Log Rank test. Univariate Cox proportional hazard ratio (HR) analysis was used to investigate the relationship between demographic, clinical, and tumor characteristics of OS and RFS rate after hepatectomy. Multivariate Cox regression analysis.

was used to control the effect of confounding variables. To estimate the adjusted effect of the ABO blood group type, the variables with P value < 0.2 [30] in univariate analysis were entered into the analysis of multivariate analysis with the backward method. The effect size with HR adjusted was reported in the 95% confidence interval (95% CI). A p-value less than 0.05 was considered a statistical significance level.

Results

Demographic and clinical characteristics

The mean age was 59.18 ± 11.38 years (range 25 to 86 years). The mean BMI was 22.7 ± 2.89 kg/m2. The majority of patients were married. The median survival was 32.5 (interquartile range (IQR): 27.4 to 37.6)months. The mean follow-up was 22.3 ± 56.7 months. The frequency of blood group types O, A, B, and AB was 219(34.2%), 201(31.4%), 148(23.1%), and 73(11.3%), respectively. Demographic and tumor characteristics were compared among four types of blood groups. Most of the patients in all four types of blood groups were 45 to 65 years old. (P: 0.65) The frequency of patients in stage I tumors was 15.4%, 18.3%, 18.2%, and 24.7% for blood groups A, O, B, and AB, respectively. (p:0.089) Nearly half of the patients in all blood groups had tumor size < 5 cm. (p: 16). The frequency of patients with serum AFP levels ≥ 400 ng/ml in patients with blood groups A, O, B, and AB was 33.8%, 34.2%, 33.8 and 14.6% respectively. (P: 0.095) There was no significant difference between the demographic, pathological findings, and tumor characteristics in patients with A and non-A blood groups (Table 1).

Table 1 Comparison of demographic and tumor characteristics based on the ABO blood group type
Full size table

Five-year survival rate

The median OS and RFS time was 37 and 31 months, respectively. The five-year survival was 25.4%. The RFS rate was 18.7% (Fig. 1). The RFS rate for patients with blood groups A, O, B, and AB was 11.4%, 24.5%, 20.9%, and 19.9%, respectively. The highest and lowest 5-year survival rates were for patients with blood groups O and A, respectively. The OS rate for patients with blood groups A, O, B, and AB was 12.9%, 31.1%, 24.1, and 29.2%, respectively (Fig. 2). The OS rate in patients with blood type A was significantly lower than in non-A patients (12.9% vs. 29.7%). (Log rank: 40.89, P: 0.001) The five-year RFS rate in patients with blood group A was significantly lower than that of non-A blood groups (21.5% vs. 11.4%). (Log rank: 10.8, P: 0.001) (Fig. 3).

Fig. 1
figure 1

Kaplan Meier of 1, 3, and five OS and RFS rate

Full size image
Fig. 2
figure 2

Kaplan–Meier of 5-year RFS and OS rate of patients based on blood type

Full size image
Fig. 3
figure 3

Kaplan-Meier of 5-year RFS and OS rate of patients based on blood type A versus non-A

Full size image

Univariate analysis

Based on the results of univariate analysis, the survival rate in patients aged 45 to 65 years was significantly better than in patients < 45 years old. (HR: 0.66, 95% CI: 0.59, 0.73, P:0.001) The 5-year survival rate is significantly related to tumor size, AFP level, the number of involved lymph nodes, differentiation grade, tumor size, hepatitis, blood group type, and metastasis were related. There was no significant association between Rh with OS and RFS (P > 0.05) (P < 0.05) Table 2.

Table 2 Predictors of 5-year survival of patients with HCC based on univariate analysis
Full size table

Multivariate analysis

To determine the effect of blood group type on survival adjusted for other tumor and demographic characteristics, all variables that had p < 0.2 in the univariate analysis were entered into the Cox multivariate analysis adjusted by the backward method. The multivariate analysis showed that the blood types A, age < 45 years, tumor size > 5 cm, poor tumor differentiation, presence of metastasis, number of lymph nodes ≤ 2, and serum AFP level ≥ 400 were associated with decreased survival of patients after hepatectomy (P < 0.05) Table 3.

Table 3 Independent predictors for survival rate by multivariate analysis
Full size table

Discussion

Although many studies have investigated the association between the ABO blood group type and the risk of HCC, limited studies have investigated the association between the ABO blood group type and the survival rate of HCC patients after hepatectomy or liver transplantation. Based on our knowledge, no comprehensive study has investigated the association between ABO blood group type with survival and RFS rate in Iranian patients with HCC after hepatectomy. Therefore, according to the issue’s importance, in this retrospective cohort study, we evaluated the effect of ABO blood group type and Rh of patients with OS and RFS rate after hepatectomy in a multicenter manner in 639 HCC patients.

According to the results of our study, the five-year OS and RFS rates of patients were 25.4% and 18.7%, respectively, indicating the disease’s lethality even after surgery. The highest and lowest survival and RFS rates were related to blood groups O and A, respectively. The 5-year RFS and OS rate in patients with blood group O was 24.5% and 31.1%, respectively, and for blood group A was 11.4% and 12.9%, which indicated the lower survival of patients with blood group A. In line with the results of our study, in 2022, M Kaibori et al. [22] showed that 5-year RF and OS rates after hepatectomy were the lowest in patients with blood type A. In addition, the results of our study showed that patients with blood type O had higher 5-year OS and RFS rates after hepatectomy. Based on the results of multivariate analysis, the 5-year survival rate in patients with blood group A compared to non-A, patients < 45 years old compared to patients ≥ 45 years old, patients with tumor size > 5 cm compared to < 5 cm, poor differentiation, the presence of metastasis before surgery, the number of lymph nodes ≤ 2, and the serum AFP level ≥ 400 was significantly lower, which was consistent with the results of studies conducted in this field [26, 31, 32]. T Wu et al., [21] by evaluating the association ABO blood group type with the survival rate of HCC patients after hepatectomy in a retrospective cohort study on 691 patients, showed that the frequency of blood types A and O were 28.8% and 37.9%, respectively. In line with the results of their study, in our study, the frequency of blood types O and A was 34.1% and 31.3%, respectively. They reported that patients with blood type O had the highest survival and patients with blood type A had the lowest survival rate, with a median survival of 39 months, which was consistent with the results of our study. In their study, they reported that in addition to the type of blood groups, tumor size > 5 cm, higher tumor stage, presence of metastasis, age < 45 years, poor tumor differentiation, and serum AFP level ≥ 400 ng/ml were significantly associated with to the decrease in the survival rate of patients after hepatectomy. In our study, in addition to these factors, a BMI ≤ 18 kg/m2 was associated with a decrease in patient survival, which can be justified due to anorexia, weakness, and poor health status of underweight patients, weakening the immune system. Several previous studies showed that BMI ≤ 18 was associated with decreased survival rates for patients with gastric cancer after surgery. Therefore, post-surgery patients’ BMI can be considered an essential independent prognostic factor [33, 34].

In another study in 2022, K Mohkam et al. [32], by examining the effect of ABO blood group type on liver cancer recurrence after liver transplantation on 925 patients with HCC, showed that the 5-year survival and recurrence rate in patients with Blood type A was significantly higher than patients with non-A blood type, which was consistent with the results of our study. In another study, K Bannangkoon et al. [35] evaluated the effect of ABO blood group type on the survival of patients with HCC treated with embolization. They showed that the patients with blood type O compared to non-O had a significantly higher survival rate, confirming our study’s results. Similar to the results of our study, Q Li et al. [29] showed that in patients with inoperable HCC after transarterial chemoembolization (TACE), the survival rate of patients with blood type O was higher than that of non-O. Based on the results of previous studies, the increased risk of cancer and the lower survival rate of patients with type A blood can be justified due to the reduced ability of the immune system of patients with type A blood to identify and attack tumor cells expressing antigens that are structurally similar to ABO antigen [36, 37]. Contrary to the results of our study, A Oral et al., [27], by examining 502 cirrhotic patients with HCC, did not report a significant relationship between the ABO blood group with survival rate. This difference can be justified due to the difference in the characteristics of the patients under investigation and the difference in the sample size in the two studies. Their study examined only cirrhotic patients, while both cirrhotic and non-cirrhotic patients were examined in our study. Another strength of our study compared to this study was the larger sample size, conducting the study in a multicenter manner, and examining more factors adjusted for other factors.

Our study had limitations and strengths that should be noted. The retrospective study design was the most important weakness of our study, which made us unable to measure several important factors and tumor markers. In addition, due to the retrospective nature and the use of patients’ medical profiles, there were missing cases in a number of variables, which can affect the estimation of the results. The design of prospective studies with a large sample size is recommended to estimate the results more accurately. Designing a comprehensive multicenter study with a high sample size, for the first time on the Iranian population, to evaluate the effect of ABO blood group type on the survival rate of patients with HCC in conditions adjusted for other variables was one of the most important strengths of our study.

Conclusion

Our study showed that the blood group type as an independent factor was related to the five-year OS and RFS rate in patients with HCC after hepatectomy. Compared to non-A, blood type A can be associated with decreased five-year OS and RFS rates in patients with HCC after surgery. The five-year OS and RFS rates were higher in patients with blood type O than non-O. Prospective studies are recommended to estimate the results more accurately.

Availability of data and materials

The datasets generated or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

HCC:

Hepatocellular carcinoma

OS:

Overall survival

RFS:

Recurrence-free survival

AFP:

Alpha-Fetoprotein

BMI:

Body mass index

TNM:

Tumor-node-metastasis index

HR:

Hazard Ratio

95% CI:

95% Confidence interval

References

  1. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–606.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ozakyol A. Global epidemiology of hepatocellular carcinoma (HCC epidemiology). J Gastrointest Cancer. 2017;48:238–40.

    Article  PubMed  Google Scholar 

  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  5. Akbulut S, Sahin TT, Ince V, Yilmaz S. Impact of COVID-19 pandemic on clinicopathological features of transplant recipients with hepatocellular carcinoma: a case-control study. World J Clin Cases. 2022;10(15):4785–98.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kucukakcali Z, Akbulut S, Colak C. Machine learning-based prediction of HBV-related hepatocellular carcinoma and detection of key candidate biomarkers. Meden Med J. 2022;37(3):255–63.

    Article  Google Scholar 

  7. Torre L, Bray F, Siegel R, Ferlay J, Lortettieulent J, Jemal A. Global cancer statistics. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 2021.

    Google Scholar 

  8. Ince V, Sahin TT, Akbulut S, Yilmaz S. Liver transplantation for hepatocellular carcinoma: historical evolution of transplantation criteria. World J Clin Cases. 2022;10(29):10413–27.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Wang D, Xiao M, Wan Z-M, Lin X, Li Q-Y, Zheng S-S. Surgical treatment for recurrent hepatocellular carcinoma: current status and challenges. World J Gastrointest Surg. 2023;15(4):544.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Poon RTP, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl. 2004;10(S2):S39–45.

    Article  PubMed  Google Scholar 

  11. Bruix J, Sherman M, American Association for the Study of liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

    Article  PubMed  Google Scholar 

  12. Yamamoto M, Katagiri S. Ariizumi Si, Kotera Y, Takahashi Y, Egawa H: Tips for anatomical hepatectomy for hepatocellular carcinoma by the G lissonean pedicle approach (with videos). J Hepatobiliary Pancreat Sci. 2014;21(8):E53–6.

    Article  PubMed  Google Scholar 

  13. Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, Mazziotti A. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234(1):71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Imai K, Allard M-A, Benitez CC, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Bismuth H, Baba H, Adam R. Early recurrence after hepatectomy for colorectal liver metastases: what optimal definition and what predictive factors? Oncologist. 2016;21(7):887–94.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Hong YM, Cho M, Yoon KT, Chu CW, Yang KH, Park YM, Rhu JH. Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma. Tumor Biol. 2017;39(10):1010428317720863.

    Article  Google Scholar 

  16. Ince V, Akbulut S, Otan E, Ersan V, Karakas S, Sahin TT, Carr BI, Baskiran A, Samdanci E, Bag HG, et al. Liver transplantation for hepatocellular carcinoma: malatya experience and proposals for expanded criteria. J Gastrointest Cancer. 2020;51(3):998–1005.

    Article  CAS  PubMed  Google Scholar 

  17. Hirokawa F, Hayashi M, Asakuma M, Shimizu T, Inoue Y, Uchiyama K. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma. Surg Oncol. 2016;25(1):24–9.

    Article  PubMed  Google Scholar 

  18. Liu Q, Li J, Liu F, Yang W, Ding J, Chen W, Wei Y, Li B, Zheng L. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy. Cancer Imaging. 2020;20(1):1–14.

    Article  Google Scholar 

  19. Lei GY, Shen L, Junnarkar SP, Huey CT, Low J, Shelat VG. Predictors of 90-day mortality following hepatic resection for hepatocellular carcinoma. Visc Med. 2021;37(2):102–9.

    Article  PubMed  Google Scholar 

  20. Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci. 2019;24:86.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kaibori M, Matsui Y, Yanagida H, Yokoigawa N, Kwon A-H, Kamiyama Y. Positive status of α-fetoprotein and des-γ-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma. World J Surg. 2004;28:702–7.

    Article  PubMed  Google Scholar 

  22. Kaibori M, Yoshii K, Matsui K, Matsushima H, Kosaka H, Yamamoto H, Aoi K, Yamaguchi T, Yoshida K, Hatanaka T. Modified albumin-bilirubin grade and alpha-fetoprotein score (mALF Score) for predicting the prognosis of hepatocellular carcinoma after hepatectomy. Cancers. 2022;14(21):5292.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gates MA, Xu M, Chen WY, Kraft P, Hankinson SE, Wolpin BM. ABO blood group and breast cancer incidence and survival. Int J Cancer. 2012;130(9):2129–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhou J, Yang L-C, He Z-Y, Li F-Y, Wu S-G, Sun J-Y. Prognostic impact of ABO blood group on the survival in patients with ovarian cancer. J Cancer. 2015;6(10):970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Razzaghi N, Seraj H, Heydari K, Azadeh H, Salehi A, Behnamfar M, Bahadori M, Ebrahimi H, Malekan M, Gholamalipour N. ABO blood groups associations with ovarian cancer: a systematic review and meta-analysis. Indian J Gynecol Oncol. 2020;18:1–10.

    Google Scholar 

  26. Wu T, Ma X-A, Wang G-Q, Li Q, Li M-J, Guo J-Y, Liang X, Ruan Z-P, Tian T, Nan K-J. ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy. Sci Rep. 2017;7(1):1–9.

    Google Scholar 

  27. Oral A, Sahin T. Prognostic role of ABO blood group and Rhesus factor in cirrhotic patients with hepatocellular carcinoma. Sci Rep. 2019;9(1):19087.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Doku GN, Agbozo WK, Annor RA, Mawudzro PE, Agbeli EE. Frequencies and ethnic distribution of ABO and RhD blood groups in the Volta region of Ghana, towards effective blood bank services. Afr Health Sci. 2022;22(1):641–7.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Chan AC, Fan ST, Poon RT, Cheung TT, Chok KS, Chan SC, Lo CM. Evaluation of the of the seventh edition American Joint Committee on Cancer tumour–node–metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB. 2013;15(6):439–48.

    Article  PubMed  Google Scholar 

  30. Akbulut S, Sahin TT, Yilmaz S. Comment on pediatric living donor liver transplantation decade progress in Shanghai: Characteristics and risks factors of mortality. World J Gastroenterol. 2020;26(30):4564–6.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Kaibori M, Yoshii K, Matsui K, Matsushima H, Kosaka H, Yamamoto H, Nakajima T, Aoi K, Yamaguchi T, Yoshida K. The prognostic impact of ABO blood group in hepatocellular carcinoma following hepatectomy. Cancers. 2023;15(11):2905.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Mohkam K, Abdallah R, N’kontchou G, Ganne N, Barbier L, Salamé E, Bucur P, Rayar M, Robin F, Boudjema K. Influence of the ABO blood group system on hepatocellular carcinoma recurrence after liver transplantation. Transplantation. 2022;106(7):1411–20.

    Article  CAS  PubMed  Google Scholar 

  33. Liu BZ, Tao L, Chen YZ, Li XZ, Dong YL, Ma YJ, Li SG, Li F, Zhang WJ. Preoperative body mass index, blood albumin and triglycerides predict survival for patients with gastric cancer. PLoS One. 2016;11(6):e0157401.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Talebi A, Mohammadnejad A, Akbari A, Pourhoseingholi MA, Doosti H, Moghimi-Dehkordi B, Agah S, Bahardoust M. Survival analysis in gastric cancer: a multi-center study among Iranian patients. BMC Surg. 2020;20:1–8.

    Article  Google Scholar 

  35. Bannangkoon K, Hongsaku K, Sripongpun P, Kaewdech A, Chamroonkul N, Tubtawee T, Piratvisuth T. ABO blood group differentials on survival in hepatocellular carcinoma patients treated with chemoembolization. Asian Pac J Cancer Prev. 2021;22(11):3685.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Yuzhalin AE, Kutikhin AG. ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia. Asian Pac J Cancer Prev. 2012;13(10):5091–6.

    Article  PubMed  Google Scholar 

  37. Ewald DR, Sumner SC. Blood type biochemistry and human disease. Wiley Interdiscip Rev Syst Biol Med. 2016;8(6):517–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

NA

Funding

Not applicable.

Author information

Author notes

  1. Maryam Najafirashed and Mansour Bahardoust are equal to the first authors.

Authors and Affiliations

  1. Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Mansour Bahardoust

  2. School of Public Health, Department of Health Care Administration and Policy, University of Nevada Las Vegas(UNLV), Las Vegas, NV, USA

    Maryam Zolfaghari Dehkharghani

  3. Ahvaz, Jundishapur University of Medical Sciences, Ahvaz, Iran

    Pouya Ebrahimi

  4. School of Medicine, Iran University of Medical Sciences, Tehran, Iran

    Maryam Najafirashed

  5. Department of Public Health, College of Health and Human Services, California State University, Fresno, CA, USA

    Safa Mousavi

  6. Department of Orthopedic Surgery, Urmia University of Medical Sciences, Urmia, Iran

    Meisam Haghmoradi

  7. Vascular Surgery Department of General Surgery, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

    Mohsen Khaleghian

  8. Department of General Surgery, School of Medicine, Iran University of Medical Sciences(IUMS), Tehran, Iran

    Adnan Tizmaghz

Authors
  1. Mansour Bahardoust
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maryam Zolfaghari Dehkharghani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pouya Ebrahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maryam Najafirashed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Safa Mousavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Meisam Haghmoradi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohsen Khaleghian
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Adnan Tizmaghz
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design: AT, MB, MZD and MN. Analysis and interpretation of data: M B,SM and MKh. Data collection: MB, AT and MH. Participation in drafting or revising the article: AT,PE, MB, MN, MKH.

Corresponding author

Correspondence to Adnan Tizmaghz.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the ethics committee of Iran University of medical science (IR.IUMS.REC.1401.925). All methods were carried out in accordance with relevant guidelines and regulations. The need for informed consent was waived by the Ethics Committee/Institutional Review Board of (Iran University of medical science).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bahardoust, M., Dehkharghani, M.Z., Ebrahimi, P. et al. Effect of ABO blood group on postoperative overall survival and recurrence-free survival rate in patients with hepatocellular carcinoma after hepatectomy: a multi-center retrospective cohort study. BMC Surg 23, 324 (2023). https://0-doi-org.brum.beds.ac.uk/10.1186/s12893-023-02236-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12893-023-02236-8

Keywords

BMC Surgery

ISSN: 1471-2482

Contact us